Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Halkes, Constantijn
[Clear All Filters]
2023
Nassani M
,
Fakih REl
,
Passweg J
,
Cesaro S
,
Alzahrani H
,
AlAhmari A
,
Bonfim C
,
Iftikhar R
,
Albeihany A
,
Halkes C
, et al.
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes.
Front Oncol. 2023;13:1135160.
PubMed
Google Scholar
2021
Alotaibi H
,
Aljurf M
,
de Latour R
,
Alfayez M
,
Bacigalupo A
,
Fakih REl
,
Schrezenmeier H
,
Ahmed SOsman
,
Gluckman E
,
Iqbal S
, et al.
Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia W
. Transplant Cell Ther. 2021.
PubMed
Google Scholar
2015
de Witte T
,
Suciu S
,
Meert, iv L
,
Halkes C
,
Selleslag D
,
Bron D
,
Amadori S
,
Willemze R
,
Muus P
,
Baron F
.
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
Ann Hematol. 2015.
PubMed
Google Scholar